Financial overview

Lytix Biopharma financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre
Pre
Pre
Pro
Pro
Created with Highcharts 9.0.1

Description

Lytix Biopharma is a biotechnology company in the clinical stage that develops new cancer immunotherapies. The company's technology is based on research in antimicrobial peptides, a defense aimed at pathogens. Lytix Biopharma's main product, LTX-315, is an oncolytic peptide for the purpose of personalizing immunotherapy. The company conducts its research and operations in Oslo.

Biotechnology